| Name | Title | Contact Details |
|---|
CipherHealth is an award-winning and proven technology solutions partner committed to enhancing communication and care throughout the patient journey. Since 2009, CipherHealth has helped shape the patient engagement category, delivering groundbreaking products to help care providers effectively and efficiently deliver quality care for their patients. CipherHealth`s suite of patient engagement programs sets new standards for care and empowers healthcare organizations to create purposeful conversations to ensure the best possible outcomes for staff members, patients, and their loved ones.
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on transforming the treatment of vascular disease and improving patient care by combining the latest medical device
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Advanced Excimer Laser-Based Vascular and Dermatological Therapies We are a medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients` quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. We currently manufacture and market two lines of products: DABRA Catheter and Laser is cleared by the U.S. FDA as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, including peripheral artery disease (PAD) and critical limb ischemia (CLI). Pharos Excimer Laser is FDA cleared as a tool used in the treatment of inflammatory skin conditions, including psoriasis, atopic dermatitis, and leukoderma.
Schwabe North America is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.